Asia Pacific market to enhance
the demand for intrauterine contraceptive devices
Asia Pacific is expected to hold
a significant share for Intrauterine
Contraceptive Devices Market owing to the rising number of unplanned
pregnancy and thereby, greater usage of such devices in this region. Moreover,
rising government initiatives focusing on improved healthcare in Asian
countries are also supporting the growth of the market. Furthermore,
technological advancements associated with these devices are accentuating their
demand in North America, followed by Europe.
Some of the major companies
indulging in the production of intrauterine contraceptive devices include Bayer
HealthCare AG, Melbea AG, DKT International, Medicines360 and Egemen
International among others. These companies are focusing on strategic initiatives
and mergers and acquisitions in order to cater to the growing need of the
target population. For instance, in 2015, Bayer HealthCare entered into a
strategic partnership with Afaxys, Inc. in order to serve women in the U.S. The
alliance will include Afaxys’ expertise and Bayer’s intrauterine device to
serve the U.S. public health contraception market.
Intrauterine contraceptive
devices - a way of birth control for a prolonged period
Intrauterine contraceptive
devices (IUD), often found in T-shape, are inserted in the uterus in order to
prevent conception. The arms of the device are fold flat helping to insert
inside the womb and its size is like a match stick, so that it fits properly
inside the womb. These devices include either copper or levonorgestrel, which
helps in birth control by creating difficulty for the sperm to fertilize the
egg. Intrauterine contraceptive devices are usually a form of long-acting
reversible contraceptives (LARC), which aids in birth control for an extended
period of time. The approximate tenure of these devices lie between 5 to 8
years. These devices have resulted in huge satisfaction rates among the users
of reversible contraceptives due to their cost-effectiveness. Copper IUD is
also used after an unprotected sex as an emergency contraceptive. Intrauterine
contraceptive devices do not have a negative impact on breastfeeding, when they
are inserted immediately after delivery. These are also used immediately after
abortion. Once removed, fertility is restored back to normal. These devices are
inserted with the help of healthcare professionals. According to an article
published by Patient, a web-based health information platform, IUDs are very
effective as 1 to 2 out of every 100 women will become pregnant after 5 years
of using the device. The non-users of this device, who are sexually active,
become pregnant and the count reaches to 80 out of 100 women within 1 year.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/53
Unplanned pregnancy is a major
driver for intrauterine contraceptive devices
Rising prevalence of unplanned
pregnancy and less side-effects pertaining to these devices are some of the
drivers impacting the demand for intrauterine contraceptive devices market.
Moreover, with the use of such devices there is no requirement of a new
contraception every day, as in case of contraceptive pills. Moreover,
intrauterine contraceptive devices do not impact the user’s mood, libido and
weight and does not even carry the risk for cancer in future. However, use of
intrauterine contraceptive devices may lead to heavy menstrual bleeding,
resulting into painful cramps, which is projected to impede the growth of the
market. In addition, the demand for contraceptive pills for shorter period
usage is expected to hinder the demand for the devices. Need for continuous
assistance of healthcare professionals is also restraining the market towards
growth.
Hormonal IUCD has low failure
rate as compared to copper IUD
On the basis of product,
intrauterine contraceptive devices (IUD) are segmented as hormonal IUD and
copper IUD. In the first year of usage of the device, failure rate with hormonal
IUD is around 0.2% whereas failure rate with copper IUD is around 0.8%.
On the basis of end use,
intrauterine contraceptive devices are classified under hospital, gynecology
clinics and others. Based on geography, the market is divided into North America,
Europe, Asia Pacific, Latin America and Middle East and Africa.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/intrauterine-contraceptive-devices-market-53
Key Developments
Focus on women’s health and
guidelines by regulatory authorities is driving the market growth. For
instance, in August 2019, the World Health Organisation (WHO) revised its
guidelines on contraceptive use in accordance with new evidence regarding high
risk of HIV in women. The new guidelines state that women should have access to
a range of options for contraception, HIV prevention, and treatment, such as
progestogen-only injectables, implants and intrauterine devices (IUDs).
Promotion strategies and educational
campaigns undertaken by key players in the market are expected to increase
health awareness among consumers, which, in turn, is expected to result in
rising demand for IUDs. For instance, in February 2019, Bayer HealthCare AG
started the first ever ad campaign regarding intrauterine devices (IUDs). The
goal of the campaign is to explain the purpose of levonorgestrel-releasing
IUDs, and also provide basic knowledge about these devices.
Similarly, social marketing
programs by market players aimed at providing family planning and HIV
prevention solutions to women and couples in low and middle income countries
are facilitating growth of the global intrauterine contraceptive devices
market. According to DKT International’s Contraceptive Social Marketing (CSM)
Statistics report released in October 2018, there has been a 6.8% increase from
2016, and a nearly 18% increase from 2015 in sale of nearly 1.8 billion
condoms, 44 million injectable contraceptives, nearly 1.4 million implants,
over 17.3 million emergency contraception (EC) pills, and 5.1 million IUDs.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/53
About
Coherent Market Insights:
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment